KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Total Non-Current Liabilities (2018 - 2024)

Historic Total Non-Current Liabilities for Aurinia Pharmaceuticals (AUPH) over the last 9 years, with Q4 2024 value amounting to $162.1 million.

  • Aurinia Pharmaceuticals' Total Non-Current Liabilities rose 179.84% to $162.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $162.1 million, marking a year-over-year increase of 179.84%. This contributed to the annual value of $162.1 million for FY2024, which is 179.84% up from last year.
  • As of Q4 2024, Aurinia Pharmaceuticals' Total Non-Current Liabilities stood at $162.1 million, which was up 179.84% from $150.5 million recorded in Q3 2024.
  • Aurinia Pharmaceuticals' 5-year Total Non-Current Liabilities high stood at $162.1 million for Q4 2024, and its period low was $29.0 million during Q1 2021.
  • For the 5-year period, Aurinia Pharmaceuticals' Total Non-Current Liabilities averaged around $84.5 million, with its median value being $52.9 million (2020).
  • In the last 5 years, Aurinia Pharmaceuticals' Total Non-Current Liabilities crashed by 2978.72% in 2021 and then soared by 25165.85% in 2023.
  • Aurinia Pharmaceuticals' Total Non-Current Liabilities (Quarter) stood at $59.3 million in 2020, then dropped by 18.62% to $48.3 million in 2021, then grew by 10.25% to $53.2 million in 2022, then surged by 199.1% to $159.2 million in 2023, then rose by 1.8% to $162.1 million in 2024.
  • Its Total Non-Current Liabilities stands at $162.1 million for Q4 2024, versus $150.5 million for Q3 2024 and $148.0 million for Q2 2024.